Daraxonrasib: A Breakthrough in Pancreatic Cancer Research

The latest results of a Phase 3 trial carried out by researchers in the US showed that daraxonrasib significantly improved overall survival in patients with advanced pancreatic cancer whose disease had progressed following previous treatment. 

Patients receiving daraxonrasib experienced a median overall survival of approximately 8.6 months, compared with 4.6 months for those receiving standard chemotherapy, effectively doubling life expectancy. For a disease where treatment options are limited and survival outcomes remain among the poorest of all major cancers, these results have been described by many experts as one of the most significant advances in pancreatic cancer treatment for decades.

Daraxonrasib is a targeted therapy designed to inhibit RAS proteins, which play a critical role in driving the growth and spread of many cancers, including pancreatic cancer. Mutations in the KRAS gene (part of the RAS family) are found in around 90% of pancreatic ductal adenocarcinomas, making KRAS one of the most important targets in pancreatic cancer research.

For decades, KRAS was considered one of the most difficult targets in cancer medicine. Researchers often referred to it as "undruggable". The development of medicines capable of targeting cancers driven by KRAS mutations has therefore been one of the most significant advances in modern oncology.

While these findings are extremely promising, it is important to recognise that daraxonrasib has not yet received regulatory approval in the UK. Regulatory authorities will need to review before the treatment can become routinely available through the NHS, and it is not yet possible to predict when that may happen.

Nevertheless the results represent an important milestone. At Pancreatic Cancer Action, we believe this breakthrough also highlights the urgent need for equitable access to molecular profiling and biomarker testing across the UK. Treatments such as daraxonrasib can only benefit patients if clinicians are able to identify those whose tumours carry the relevant genetic alterations.

We want to ensure that every eligible patient, regardless of where they live in England, Scotland, Wales or Northern Ireland, has access to the testing, expertise and treatments that could improve both survival and quality of life.

Behind every research breakthrough are the families whose lives have been devastated by pancreatic cancer. The parents who may never see their children grow up, the partners robbed of precious years together and the families whose plans and futures are changed forever by this disease.

Pancreatic Cancer Action welcomes these results as a potential significant step forward, but we need more research to find targeted therapies for those with pancreatic cancer.

We will continue to champion early diagnosis and faster adoption of innovations such as these.